Clene Inc (CLNN)

$4.79 -0.10 (-2.04%)
Market Cap 40.04M
Revenue (ttm) 650,000.00
Net Income (ttm) -49.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,615.38%
Debt to Equity Ratio -0.40
Volume 32,300
Avg Vol 88,594
Day's Range N/A - N/A
Shares Out 8.36M
Stochastic %K 3%
Beta 0.25
Analysts Strong Sell
Price Target $45.17

Latest News on CLNN

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Dec 10, 2024, 8:30 AM EST - 5 weeks ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 30, 2024, 8:30 AM EDT - 3 months ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 16, 2024, 8:30 AM EDT - 4 months ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 4 months ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 8, 2024, 8:00 AM EDT - 5 months ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Aug 7, 2024, 8:23 AM EDT - 5 months ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Clene to Present at the Emerging Growth Conference

Jul 12, 2024, 10:34 AM EDT - 6 months ago

Clene to Present at the Emerging Growth Conference

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 11, 2024, 9:00 AM EDT - 6 months ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Clene Announces 1-for-20 Reverse Stock Split

Jul 9, 2024, 8:00 AM EDT - 6 months ago

Clene Announces 1-for-20 Reverse Stock Split

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 24, 2024, 8:00 AM EDT - 7 months ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 21, 2024, 7:09 AM EDT - 7 months ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Jun 18, 2024, 7:00 AM EDT - 7 months ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 28, 2024, 7:30 AM EDT - 8 months ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

Clene to Present at Upcoming May Conferences

May 14, 2024, 8:00 AM EDT - 8 months ago

Clene to Present at Upcoming May Conferences

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

May 8, 2024, 8:00 AM EDT - 9 months ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Apr 16, 2024, 4:01 PM EDT - 9 months ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 15, 2024, 8:00 AM EDT - 11 months ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Mar 13, 2024, 8:00 AM EDT - 11 months ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Feb 29, 2024, 8:00 AM EST - 11 months ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 11:25 AM EST - 1 year ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Dec 14, 2023, 8:36 AM EST - 1 year ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Nov 7, 2023, 8:00 AM EST - 1 year ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Oct 5, 2023, 10:00 AM EDT - 1 year ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 28, 2023, 8:00 AM EDT - 1 year ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Sep 25, 2023, 4:00 PM EDT - 1 year ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Sep 25, 2023, 7:00 AM EDT - 1 year ago

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Clene to Present at Upcoming September Conferences

Aug 30, 2023, 8:20 AM EDT - 1 year ago

Clene to Present at Upcoming September Conferences

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Aug 29, 2023, 7:00 AM EDT - 1 year ago

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Aug 14, 2023, 8:00 AM EDT - 1 year ago

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Aug 2, 2023, 7:00 AM EDT - 1 year ago

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Jun 26, 2023, 8:00 AM EDT - 1 year ago

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Jun 21, 2023, 9:20 AM EDT - 1 year ago

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Clene Announces Pricing of $40 Million Public Offering

Jun 16, 2023, 8:00 AM EDT - 1 year ago

Clene Announces Pricing of $40 Million Public Offering

Clene Announces Launch of Proposed Public Offering

Jun 15, 2023, 4:38 PM EDT - 1 year ago

Clene Announces Launch of Proposed Public Offering

Clene's CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

Jun 15, 2023, 4:29 PM EDT - 1 year ago

Clene's CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

Clene to Participate in the Maxim Group Virtual Healthcare Conference

Jun 15, 2023, 7:00 AM EDT - 1 year ago

Clene to Participate in the Maxim Group Virtual Healthcare Conference

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

May 12, 2023, 4:00 PM EDT - 1 year ago

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

ALS and MS Clinical Data from Clene's CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

Apr 25, 2023, 4:05 PM EDT - 1 year ago

ALS and MS Clinical Data from Clene's CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting

Apr 11, 2023, 8:00 AM EDT - 1 year ago

Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting

Clene Appoints Neurology Expert to Executive Team

Mar 16, 2023, 9:46 AM EDT - 2 years ago

Clene Appoints Neurology Expert to Executive Team

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

Mar 13, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial

Mar 9, 2023, 6:30 AM EST - 2 years ago

CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

Mar 8, 2023, 4:10 PM EST - 2 years ago

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

Clene Nanomedicine to Participate in Roth's 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

Mar 7, 2023, 8:00 AM EST - 2 years ago

Clene Nanomedicine to Participate in Roth's 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity

Feb 13, 2023, 7:00 AM EST - 2 years ago

Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

Jan 11, 2023, 8:00 AM EST - 2 years ago

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Dec 27, 2022, 4:01 PM EST - 2 years ago

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg